Safety, trade concerns weigh on China biotechs

Drug safety concerns, the latest threats in the U.S.-China trade war and slowing economic growth pushed Chinese biopharma stock lower this week.

The Shenzhen Stock Exchange Friday publicly reprimanded six senior executives at Changsheng Bio-Technology Co. Ltd. (SZSE:002680), which is at the center of a vaccine scandal in the country. On July 15, China's State Drug

Read the full 550 word article

How to gain access

Continue reading with a
two-week free trial.